Insulet/$PODD

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Insulet

Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device and that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetics are using it worldwide.

Ticker

$PODD
Primary listing

Industry

Health Care Equipment and Supplies

Employees

3,900

Insulet Metrics

BasicAdvanced
$20B
51.47
$5.55
1.35
-

What the Analysts think about Insulet

Analyst ratings (Buy, Hold, Sell) for Insulet stock.

Bulls say / Bears say

Insulet's Omnipod 5 device is the first system to receive clearance for managing both type 1 and type 2 diabetes, expanding its market reach. (reuters.com)
The company reported a 28.8% increase in total revenue for Q1 2025, surpassing analyst estimates and indicating strong product demand. (reuters.com)
Insulet raised its full-year revenue growth guidance to between 19% and 22%, reflecting confidence in sustained growth. (reuters.com)
The U.S. Appeals Court removed a preliminary injunction against EOFlow, potentially increasing competition in the tubeless insulin pump market. (reuters.com)
Short-seller Blue Orca Capital revealed a short position in Insulet, citing concerns over the company's market position amid rising competition. (reuters.com)
Investor concerns persist regarding the impact of GLP-1 drugs on insulin pump demand, which could affect Insulet's future sales. (reuters.com)
Data summarised monthly by Lightyear AI. Last updated on 11 Jul 2025.

Insulet Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Insulet Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $PODD

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs